Format

Send to

Choose Destination
J Antimicrob Chemother. 2010 Dec;65(12):2598-601. doi: 10.1093/jac/dkq353. Epub 2010 Sep 22.

Repurposing FDA-approved drugs to combat drug-resistant Acinetobacter baumannii.

Author information

1
Center for Infectious Disease and Biodefense Research, SRI International, Menlo Park, CA, USA.

Abstract

OBJECTIVE:

The rising occurrence of drug-resistant pathogens accentuates the need to identify novel antibiotics. We wanted to identify new scaffolds for drug discovery by repurposing FDA-approved drugs against Acinetobacter baumannii, an emerging Gram-negative nosocomial drug-resistant pathogen.

MATERIALS AND METHODS:

In this study, we screened 1040 FDA-approved drugs against drug-susceptible A. baumannii ATCC 17978 and drug-resistant A. baumannii BAA-1605.

RESULTS AND DISCUSSION:

Twenty compounds exhibited significant antimicrobial activity (MIC ≤8 mg/L) against ATCC 17978 while only five compounds showed such activity against BAA-1605. Among the most notable results, tyrothricin, a bactericidal antibiotic typically active only against Gram-positive bacteria, exhibited equipotent activity against both strains.

CONCLUSION:

The paucity of identified compounds active against drug-resistant A. baumannii exemplifies its ability to resist antimicrobials as well as the resilience of drug-resistant Gram-negative pathogens. Repurposing of approved drugs is a viable alternative to de novo drug discovery and development.

PMID:
20861141
DOI:
10.1093/jac/dkq353
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center